

20/639
8

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))					
--	--	--	--	--	--

Docket No.
17813 (PC26865A)

In Re Application Of: **Francesco Casuscelli, et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/015,630	December 17, 2001	Jon D. Epperson	23389	1639	7565

Title:

**HYDROXYPHENYL-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PROCESS FOR
THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM**



Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
 (Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
 17813 (PC26865A)

In Re Application of: **Francesco Casuscelli, et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/015,630	December 17, 2001	Jon D. Epperson	23389	1639	7565

Title:

**HYDROXPHENYL-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PROCESS FOR
 THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of **\$180.00** is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. **19-1013/SSMP** as described below.
 - Charge the amount of
 - Credit any overpayment.
 - Charge any additional fee required.
- Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*


I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No.) on

 (Date)

 Signature

 Typed or Printed Name of Person Signing Certificate

*This certificate may only be used if paying by deposit account.



Signature

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

 October 13, 2005
 (Date)



 Signature of Person Mailing Correspondence

Peter I. Bernstein

 Typed or Printed Name of Person Mailing Certificate

Dated: **October 13, 2005**

Peter I. Bernstein

Registration No. 43,497

Scully, Scott, Murphy & Presser
 400 Garden City Plaza, Suite 300
 Garden City, New York 11530
 516-742-4343

CC:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Francesco Casuscelli, et al.

Examiner: Jon D. Epperson

Serial No: 10/015,630

Art Unit: 1639

Filed: December 17, 2001

Docket: 17813 (PC26865A)

For: HYDROXPHENYL-PYRAZOLE
DERIVATIVES ACTIVE AS KINASE
INHIBITORS PROCESS FOR THEIR
PREPARATION AND PHARMACEUTICAL
COMPOSITIONS COMPRISING THEM

Dated: October 13, 2005

Confirmation No.: 7565

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT


In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. Heilbron I.M. et al., "Studies in the Pyrone Series. Part I-Alkyl Benzo- γ -Pyrones and α -Naphtha- γ -Pyrones", *J. Chem. Soc.*, 284:1311-1315 (1935), XP-001145490;
2. Allah H.M.F. et al., "Potential Antineoplastic Agents-Part 1: Substituted Thiocarbamoyl-3,5-Disubstituted Pyrazoles", *Pharmazie*, 35(H-12):799-800 (1980), XP-002952602;

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

Dated: October 13, 2005



Peter I. Bernstein

10/19/2005 MBELETE1 0000029 10015630

01 FC:1806

180.00 0P

3. Murthy M.S.R. et al., "Synthesis of Heterocyclic Compounds-Part Iv^a- Preparation and Antimicrobial Activity of Some 3,5-Diarylpyrazole Derivatives", *Indian Drugs*, 22(9):462-464 (1985), XP-002232136;
4. Murthy M.S.R. et al., "Synthesis of Heterocyclic Compounds-Part II- Preparation and Antibacterial Activity of Some 3,5-Diarylpyrazoles", *Indian Drugs*, 22(5):247-251 (1985), XP-002232137;
5. Silverman R.B., "Drug Development: Lead Modificaiton", *The Organic Chemistry of Drug Design and Drug Action*, pages 19-23 (1992);
6. Nawwar G.A.M. et al., "Synthesis and Molluscicidal Activity of New Derivatives of 1-(Hydroxy/Substituted Phenyl)-3-Arylpropenones", *Arch. Pharm.*, 326:831-836 (1993), XP-009006119;
7. Hamed A.A. et al., "Reactions with 2-Methylchromones", *Anales de Quimica*, 90(5-6):359-364 (1994);
8. Hosoi T. et al., "Evidence for cdk5 as a Major Activity Phosphorylating Tau Protein in Porcine Brain Extract", *J. Biochem.* 117(4):741-749 (1995);
9. Cohen P., "The Development and Therapeutic Potential of Protein Kinase Inhibitors", *Current Opinion in Chemical Biology*, 3:459-465 (1999);
10. Naik S.M. et al., "Synthesis of Some New 1-H-3-(2'-Hydroxy-5'-Methyl-4', 6'-Dibromophen-1'-yl)-5-Substituted Phenyl-2-Pyrazolines and Related Compounds and Their Antibacterial Activity", *11(4):1537-1539 (1999)*;
11. Naik V.R. et al., "Synthesis of Some New Pyrazoline Derivatives and Related Compounds from Chalcones and Their Antibacterial Activity", *Asian Journal of Chemistry*, 11(4):1522-1524 (1999);
12. Rampey M.E. et al., "A New Series of Proton/Charge Transfer Molecules: Synthesis and Spectral Studies of 2-(5-Aryl-1-Carbomethoxy-1H-Pyrazol-3-yl)Phenols", *Photochemistry and Photobiology*, 70(2):176-183 (1999);
13. PCT International Publication No. WO 00/07996, published February 17, 2000;
14. Mogilaiah K. et al., "Synthesis and Antibacterial Activity of Pyrazole and 1,3,4-Oxadiazole Derivatives of 2-Phenyl-1,8-Naphthyridine", *Indian Journal of Chemistry*, 40B:43-48 (2001);

15. Thakare S.S. et al., "Dehydrogenation of 1-H-3-(2"-Hydroxy-3"-Substituted-5"-Chlorophenyl)5-(2'-Furyl)-2-Pyrazolines and Their Derivatives with Antimicrobial Activities", *Oriental Journal of Chemistry*, 17(1):127-130 (2001), XP-002232135; and
16. Thakare S.S. et al., "Synthesis of 1-H-3-(2"-Hydroxy-3"-Subsituted-5"-Chlorophenyl)-5-(2'-Furyl)-2-Pyrazoles and Their Derivatives", *Asian Journal of Chemistry*, 13(1):237-240 (2001).

Reference nos. 1-4, 6, 13 and 15 were cited in a Search Report dated April 3, 2003 received from the European Patent Office. Applicants are submitting copies of the above-cited references, together with a copy of the Search Report. The relevance of above-identified reference nos. 1-4, 6, 13 and 15 has been described in the Search Report. The relevance of above-identified reference nos. 7-12 and 14 has been described in the specification.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(c), a check in the amount of \$180.00 is enclosed.

Respectfully submitted,




Peter I. Bernstein
Registration No.: 43,497

Scully, Scott, Murphy & Presser
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343

YL:dg

Form PTO-1449 (REV. 7-80) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Atty. Docket No. (Optional) 17813 (PC26865A)	Application Number 10/015,630				
LIST OF PRIOR ART CITED BY APPLICANT <i>(Use several sheets if necessary)</i>		Applicant(s) Francesco Casuscelli, et al.					
		Filing Date December 17, 2001	Group Art Unit 1639				
FOREIGN PATENT DOCUMENTS							
REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 00/07996	2/17/00	PCT				
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	Heilbron I.M. et al., "Studies in the Pyrone Series. Part I-Alkyl Benzo- γ -Pyrones and α -Naphtha- γ -Pyrones", <i>J. Chem. Soc.</i> , 284:1311-1315 (1935), XP-001145490						
	Allah H.M.F. et al., "Potential Antineoplastic Agents-Part 1: Substituted Thiocarbamoyl-3,5-Disubstituted Pyrazoles", <i>Pharmazie</i> , 35(H-12):799-800 (1980), XP-002952602						
	Murthy M.S.R. et al., "Synthesis of Heterocyclic Compounds-Part Iv ^a -Preparation and Antimicrobial Activity of Some 3,5-Diarylpyrazole Derivatives", <i>Indian Drugs</i> , 22(9):462-464 (1985), XP-002232136						
	Murthy M.S.R. et al., "Synthesis of Heterocyclic Compounds-Part II-Preparation and Antibacterial Activity of Some 3,5-Diarylpyrazoles", <i>Indian Drugs</i> , 22(5):247-251 (1985), XP-002232137						
	Silverman R.B., "Drug Development: Lead Modificaiton", <i>The Organic Chemistry of Drug Design and Drug Action</i> , pages 19-23 (1992)						
	Nawwar G.A.M. et al., "Synthesis and Molluscicidal Activity of New Derivatives of 1-(Hydroxy/Substituted Phenyl)-3-Arylpropenones", <i>Arch. Pharm.</i> , 326:831-836 (1993), XP-009006119						
	Hamed A.A. et al., "Reactions with 2-Methylchromones", <i>Anales de Quimica</i> , 90(5-6):359-364 (1994)						
EXAMINER			DATE CONSIDERED				
<small>* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>							

LIST OF PRIOR ART
CITED BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No. (Optional)

17813 (PC26865A)

Application Number

10/015,630

Applicant(s)

Francesco Casuscelli, et al.

Filing Date

December 17, 2001

Group Art Unit

1639

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Hosoi T. et al., "Evidence for cdk5 as a Major Activity Phosphorylating Tau Protein in Porcine Brain Extract", *J. Biochem.* 117(4):741-749 (1995)

Cohen P., "The Development and Therapeutic Potential of Protein Kinase Inhibitors", *Current Opinion in Chemical Biology*, 3:459-465 (1999)

Naik S.M. et al., "Synthesis of Some New 1-H-3-(2'-Hydroxy-5'-Methyl-4', 6'-Dibromophenyl-1'-yl)-5-Substituted Phenyl-2-Pyrazolines and Related Compounds and Their Antibacterial Activity", *11(4):1537-1539* (1999)

Naik V.R. et al., "Synthesis of Some New Pyrazoline Derivatives and Related Compounds from Chalcones and Their Antibacterial Activity", *Asian Journal of Chemistry*, 11(4):1522-1524 (1999)

Rampey M.E. et al., "A New Series of Proton/Charge Transfer Molecules: Synthesis and Spectral Studies of 2-(5-Aryl-1-Carbomethoxy-1H-Pyrazol-3-yl)Phenols", *Photochemistry and Photobiology*, 70(2):176-183 (1999)

Mogilaiah K. et al., "Synthesis and Antibacterial Activity of Pyrazole and 1,3,4-Oxadiazole Derivatives of 2-Phenyl-1,8-Naphthyridine", *Indian Journal of Chemistry*, 40B:43-48 (2001)

Thakare S.S. et al., "Dehydrogenation of 1-H-3-(2"-Hydroxy-3"-Substituted-5"-Chlorophenyl)5-(2'-Furyl)-2-Pyrazolines and Their Derivatives with Antimicrobial Activities", *Oriental Journal of Chemistry*, 17(1):127-130 (2001), XP-002232135

Thakare S.S. et al., "Synthesis of 1-H-3-(2"-Hydroxy-3"-Substituted-5"-Chlorophenyl)-5-(2'-Furyl)-2-Pyrazoles and Their Derivatives", *Asian Journal of Chemistry*, 13(1):237-240 (2001)

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.